A long-term, trust-based CDMO partnership can support cell and gene therapy developers from early process development through GMP manufacturing and commercial supply.
Advanced therapy developers, particularly in the cell and gene therapy space, face intense pressure to balance speed, cost, and GMP compliance as they move from early research into the clinic. An experienced CDMO can mitigate these challenges by offering stage-appropriate support, platform technologies, and flexible manufacturing approaches that accommodate both early academic processes and more mature, transfer-ready programs. Hartmut Tintrup, Executive Director, Commercial Development, FUJIFILM Biotechnologies, highlights how establishing a trusted, financially stable partner with end-to-end capabilities early on can reduce tech transfer risk and enable a smoother path to commercial manufacturing.
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
